respiratori
viral
infect
rvi
common
caus
mild
ill
immunocompet
children
adult
rare
occurr
signific
morbid
mortal
complic
common
young
old
underli
lung
diseas
howev
rvi
increasingli
recogn
caus
morbid
mortal
recipi
hematopoiet
stem
cell
transplant
hsct
solid
organ
transplant
sot
diagnost
techniqu
respiratori
syncyti
viru
rsv
parainfluenza
influenza
adenoviru
clinic
avail
decad
infect
known
caus
seriou
diseas
transplant
recipi
modern
molecular
technolog
made
possibl
detect
rvi
includ
human
metapneumoviru
coronaviru
bocaviru
role
virus
caus
seriou
diseas
transplant
recipi
still
work
articl
review
current
inform
regard
epidemiolog
pathogenesi
clinic
present
diagnosi
treatment
infect
well
aspect
clinic
signific
rvi
uniqu
hsct
sot
respiratori
viral
infect
rvi
transplant
commun
acquir
respiratori
viru
carv
respiratori
syncyti
viru
influenza
parainfluenza
respiratori
viral
infect
rvi
signific
caus
morbid
mortal
immunocompromis
host
tradit
laboratori
diagnosi
respiratori
virus
difficult
limit
rel
virus
viru
isol
cell
line
gener
provid
result
day
direct
fluoresc
antibodi
dfa
test
use
nasopharyng
aspir
swab
also
avail
clinic
laboratori
provid
rapid
result
hour
howev
test
commonli
limit
influenza
parainfluenza
respiratori
syncyti
viru
rsv
adenoviru
adv
sensit
detect
may
also
limit
past
decad
nucleic
acid
amplif
test
nat
play
lead
role
diagnosi
rvi
multiplex
polymeras
chain
reaction
pcr
microbead
detect
dna
microarray
capabl
search
sever
virus
one
test
gener
nat
test
sensit
method
detect
virus
eg
human
bocaviru
depend
nat
studi
rvi
transplant
recipi
retrospect
focu
symptomat
patient
util
cultur
dfa
test
diagnosi
method
like
lead
underestim
incid
overestim
sever
difficult
appli
clinic
practic
today
review
describ
current
knowledg
rvi
relat
hematopoiet
stem
cell
transplant
hsct
solid
organ
transplant
sot
recipi
provid
reader
knowledg
requir
make
inform
decis
care
patient
rsv
common
caus
season
rvi
immunocompet
host
age
unit
state
rsv
infect
occur
month
novemb
april
among
healthi
nonelderli
adult
rsv
usual
caus
mild
selflimit
upper
respiratori
tract
ill
howev
rsv
common
caus
lower
respiratori
tract
infect
lrti
children
younger
year
almost
children
infect
rsv
year
age
reinfect
common
rsv
also
frequent
often
unrecogn
caus
lrti
elderli
healthi
elderli
infect
annual
elderli
patient
hospit
rsv
infect
length
stay
need
intens
care
similar
seen
influenza
mortal
rate
respect
also
similar
addit
risk
factor
lower
respiratori
tract
diseas
includ
age
less
month
preterm
birth
infant
lung
diseas
cardiopulmonari
diseas
immunocompromis
individu
rsv
infect
also
common
healthi
nonelderli
adult
usual
caus
mild
selflimit
upper
respiratori
tract
infect
uri
among
hsct
recipi
rsv
common
caus
season
respiratori
tract
infect
hsct
recipi
infect
rsv
especi
vulner
infect
lower
respiratori
tract
factor
report
elev
risk
lrti
includ
allogen
transplant
mismatchedunrel
transplant
graft
versu
host
diseas
myeloabl
regimen
advanc
age
infect
within
month
transplant
prolong
lymphopenia
rsv
lrti
strong
predictor
mortal
hsct
patient
associ
mortal
report
rang
gener
trend
improv
rate
surviv
time
may
part
explain
increas
awar
improv
care
patient
incid
sever
rsv
infect
lung
transplant
recipi
describ
multipl
retrospect
seri
one
prospect
studi
lung
transplant
recipi
eight
patient
contract
rsv
infect
singl
season
howev
similar
singleseason
studi
lung
transplant
recipi
seven
diagnos
rsv
infect
importantli
sever
lrti
describ
lung
transplant
recipi
mortal
rate
attribut
rsv
rang
studi
report
incid
spectrum
rsv
infect
sot
recipi
lung
recipi
spars
studi
pediatr
renal
transplant
recipi
found
spectrum
rsv
infect
similar
report
normal
children
anoth
studi
pediatr
liver
transplant
recipi
also
report
clinic
spectrum
rsv
infect
similar
seen
normal
children
conclud
earli
onset
infect
within
day
transplant
preexist
lung
diseas
risk
factor
sever
diseas
augment
immunosuppress
age
less
year
also
associ
increas
sever
diseas
among
sot
recipi
transmiss
rsv
commonli
occur
direct
inocul
mouth
nose
eye
contact
viruscontain
secret
fomit
howev
spread
via
larg
aerosol
droplet
also
implic
rsv
surviv
sever
hour
hand
contamin
surfac
nosocomi
transmiss
rsv
report
hsct
unit
hsct
clinic
durat
viral
shed
may
prolong
hsct
patient
rang
day
one
studi
replic
nasopharynx
rsv
extend
lower
respiratori
tract
presum
aspir
secret
patholog
find
includ
prolifer
bronchial
epithelium
epitheli
necrosi
infiltr
monocyt
tcell
center
airway
pulmonari
arteriol
find
neutrophilia
bronchoalveolar
lavag
bal
fluid
also
describ
rsv
infect
restrict
respiratori
epithelium
rare
isol
extrapulmonari
tissu
immun
respons
rsv
includ
vigor
product
cytokin
chemokin
includ
beta
tumor
necrosi
factor
alpha
concentr
immun
respons
cytokineschemokin
respiratori
secret
may
correl
sever
diseas
howev
yet
evid
whether
immun
respons
cytokineschemokin
directli
caus
damag
mere
repres
stronger
immun
respons
stimul
higher
burden
rsv
rsv
one
common
caus
rvi
transplant
recipi
initi
manifest
rsv
infect
usual
limit
upper
respiratori
tract
symptom
includ
congest
rhinorrhea
howev
among
immunocompromis
patient
rsv
upper
uri
may
quickli
progress
lrti
includ
lifethreaten
pneumonia
accord
one
recent
literatur
review
hsct
patient
progress
rate
lrti
untreat
patient
moreov
risk
mortal
high
among
patient
progress
lrti
rsv
attribut
mortal
among
hsct
patient
diagnos
lrti
among
patient
rsv
lrti
incid
coinfect
anoth
virul
pathogen
may
lower
rsv
rel
respiratori
virus
one
studi
hsct
patient
incid
coinfect
patient
infect
rsv
compar
infect
influenza
infect
parainfluenza
anoth
studi
hsct
patient
lrti
due
rsv
develop
invas
aspergillosi
oppos
influenza
parainfluenza
infect
respect
rsv
infect
may
uniqu
associ
subsequ
pulmonari
sequela
among
infant
sever
rsv
infect
associ
increas
risk
reactiv
airway
diseas
moreov
even
among
previous
healthi
adult
rsv
infect
associ
alter
airway
activ
week
infect
pulmonari
sequela
follow
rsv
infect
immunocompromis
patient
adequ
studi
notabl
howev
rsv
lrti
first
day
follow
hsct
associ
increas
risk
subsequ
airflow
declin
one
studi
rsv
lrti
also
associ
high
risk
graft
dysfunct
develop
bronchiol
obliteran
syndrom
bo
lung
transplant
recipi
one
hold
high
clinic
suspicion
rsv
set
lower
respiratori
tract
diseas
known
circul
rsv
commun
usual
winter
season
laboratori
diagnosi
made
analysi
respiratori
secret
eg
nasal
wash
bal
standard
viral
cultur
techniqu
cell
remain
gold
standard
rsv
identif
method
take
day
rapid
antigen
assay
avail
test
may
lack
sensit
adult
pcrbase
assay
also
perform
rapidli
sensit
test
rsv
typic
includ
multiplex
pcr
assay
multitud
respiratori
virus
vaccin
develop
rsv
paramyxovirus
hamper
develop
vaccineassoci
pulmonari
inflamm
earli
trial
current
licens
vaccin
avail
clinic
use
palivizumab
monoclon
rsvspecif
antibodi
shown
reduc
hospit
rate
among
children
high
risk
rsv
infect
multicent
random
control
trial
hsct
recipi
palivizumab
appear
safe
may
benefici
prevent
andor
treatment
rsv
infect
howev
clinic
trial
need
determin
efficaci
prevent
rsv
infect
highrisk
transplant
recipi
although
consensu
standard
treatment
algorithm
rsv
ribavirin
mainstay
treatment
algorithm
seriou
rsv
infect
ribavirin
alon
oral
iv
inhal
ribavirin
associ
improv
surviv
hsct
recipi
rsv
infect
limit
success
also
report
inhal
ribavirin
alon
inhal
ribavirin
intraven
immunoglobulin
ivig
rsvspecif
immun
globulin
inhal
ribavirin
iv
palivizumab
unfortun
treatment
studi
rsv
plagu
lack
random
small
sampl
size
recent
review
condens
publish
data
regard
outcom
rsv
infect
review
author
found
ribavirin
treatment
regardless
form
associ
much
lower
rate
progress
uri
lrti
compar
therapi
also
true
mortal
patient
lrti
treat
addit
immunomodul
ivig
rsv
immun
globulin
inhal
ribavirin
associ
trend
better
outcom
patient
treat
inhal
ribavirin
alon
conclus
evid
obtain
futur
clinic
trial
author
recommend
hsct
patient
rsv
uri
least
one
risk
factor
progress
lrti
treat
either
inhal
oral
ribavirin
moreov
patient
rsv
lrti
treat
combin
therapi
ivig
palivizumab
reduc
risk
rsvassoci
mortal
sever
new
agent
earli
clinic
trial
rsv
alnylam
pharmaceut
cambridg
promis
compound
develop
compound
inhibit
replic
rsv
interrupt
synthesi
viral
nucleocapsid
protein
nprotein
phase
trial
way
parainfluenza
viru
piv
singlestrand
envelop
rna
viru
paramyxovirida
famili
may
caus
clinic
signific
diseas
normal
immunocompromis
host
four
genet
distinct
serotyp
parainfluenza
type
type
type
type
order
frequenc
isol
differ
serotyp
vari
season
preval
clinic
diseas
found
yearround
increas
incid
spring
summer
area
endem
associ
bronchiol
pneumonia
found
epidem
usual
autumnfal
winter
result
childhood
laryngotracheobronch
croup
type
well
studi
least
common
serotyp
isol
piv
infect
airway
epitheli
cell
children
infect
usual
mild
rang
characterist
laryngotracheobronch
uri
howev
bronchiol
pneumonia
also
occur
lrti
typic
affect
case
infant
children
adult
also
infect
transmit
diseas
primari
site
infect
children
adult
mucou
membran
nose
throat
incub
period
rang
day
distal
spread
viru
throughout
respiratori
epithelium
found
within
day
later
typic
transmiss
occur
person
person
presum
transfer
secret
respiratori
tract
direct
contact
larg
droplet
reinfect
occur
usual
result
mild
ill
piv
respiratori
virus
may
predispos
secondari
bacteri
infect
via
epitheli
damag
impair
ciliari
function
andor
alter
normal
host
immuneinflammatori
respons
addit
bacteri
infect
may
promot
increas
express
bacteri
receptor
pivinfect
cell
regard
hsct
two
larg
retrospect
studi
perform
univers
minnesota
fred
hutchinson
cancer
research
center
center
demonstr
piv
respiratori
infect
found
hsct
respect
first
studi
patient
piv
adult
children
studi
limit
uri
wherea
present
simultan
uri
lrti
studi
frequenc
lrti
due
piv
rang
combin
recent
studi
incid
piv
infect
posthsct
diagnos
standard
method
dfa
viral
cultur
vari
howev
new
technolog
use
detect
piv
via
pcr
method
demonstr
higher
incid
previous
report
instanc
one
seri
demonstr
hsct
recipi
develop
piv
although
includ
asymptomat
case
median
interv
transplant
piv
infect
rang
day
serotyp
commonli
isol
hsct
account
case
wherea
account
respect
infect
rare
case
infect
among
hsct
recipi
occur
spring
summer
month
infect
peak
commun
howev
yearround
occurr
possibl
sourc
piv
infect
usual
appar
piv
produc
nonspecif
symptom
immunocompromis
normal
host
may
go
unrecogn
render
nosocomi
transmiss
difficult
detect
sinc
reactiv
without
reinfect
confirm
nosocomi
transmiss
appear
mode
infect
hospitalacquir
piv
infect
defin
occur
day
admiss
account
piv
infect
larg
hsct
popul
studi
suggest
intens
immunosuppress
lymphopenia
may
primari
factor
associ
piv
infect
pneumonia
hsct
recipi
multivari
analysi
identifi
receipt
unrel
transplant
risk
factor
piv
acquisit
howev
dose
corticosteroid
time
piv
infect
acquisit
primari
factor
associ
develop
pneumonia
among
allogen
autolog
hsct
recipi
yet
anoth
studi
hsct
patient
receiv
nonmyeloabl
condit
demonstr
cumul
probabl
rvi
month
posttranspl
frequent
isol
organ
case
among
sot
recipi
major
publish
data
involv
lung
transplant
recipi
ltr
one
studi
ltr
underw
serial
bal
sampl
luminex
xtag
respiratori
viral
panel
assay
luminex
corpor
austin
tx
includ
piv
patient
piv
asymptomat
anoth
retrospect
studi
ltr
univers
pittsburgh
medic
center
piv
found
via
cultur
dfa
ltr
median
time
diagnosi
year
occur
year
transplant
piv
serotyp
includ
incid
piv
sot
recipi
well
studi
primari
site
infect
piv
mucou
membran
nose
throat
incub
period
rang
day
distal
spread
viru
throughout
respiratori
epithelium
detect
day
later
extent
infect
usual
correl
sever
diseas
instanc
mild
uri
associ
limit
infect
nasopharynx
wherea
sever
diseas
involv
spread
infect
lower
respiratori
airway
usual
infect
larynx
upper
trachea
may
caus
croup
associ
bronchiol
pneumonia
thu
infect
distal
airway
interestingli
anim
model
demonstr
piv
directli
injur
airway
epithelium
importantli
studi
also
suggest
indirect
injuri
due
inflammatori
mediat
host
immun
respons
like
respons
airway
reactiv
bronchiol
overal
lung
injuri
clinic
characterist
piv
infect
transplant
popul
patient
similar
infect
respiratori
viru
rsv
typic
sign
symptom
piv
infect
hsct
recipi
includ
fever
cough
coryza
wateri
eye
sore
throat
wheez
sputum
dyspnea
radiograph
infiltr
sinu
headach
sinu
congest
sinu
opacif
muscl
ach
among
hsct
recipi
lrti
due
piv
typic
find
highresolut
chest
comput
tomographi
multipl
small
nodul
mm
diamet
without
cavit
peribronchi
distribut
howev
find
seen
opportunist
infect
radiograph
infiltr
also
seen
usual
suggest
late
phase
infect
coinfectionsuperinfect
risk
factor
poor
outcom
hsct
recipi
infect
piv
includ
sepsi
multiorgan
failur
pulmonari
copathogen
need
mechan
ventil
coinfect
respiratori
pathogen
common
patient
piv
lrti
even
uri
associ
increas
mortal
larg
cohort
hsct
recipi
howev
associ
mortal
greater
lrti
fact
overal
mortal
lrti
day
day
diagnosi
pneumonia
multipl
studi
cite
mortal
rate
associ
infect
rang
piv
involv
lrt
associ
increas
mortal
eg
progress
uri
lrti
associ
use
highdos
system
steroid
lymphopenia
larg
retrospect
studi
develop
lrti
driven
primarili
administr
corticosteroid
graft
versu
host
diseas
gvhd
data
suggest
taper
corticosteroid
time
uri
diagnosi
may
one
strategi
prevent
progress
pneumonia
pulmonari
sequela
anoth
signific
complic
piv
infect
hsct
popul
larg
retrospect
studi
involv
hsct
recipi
develop
airflow
declin
defin
year
declin
percentag
predict
forc
expiratori
volum
second
fev
year
year
fev
forc
vital
capac
fvc
ratio
among
patient
develop
piv
uri
develop
airflow
declin
year
seven
patient
develop
piv
lrti
six
develop
airflow
declin
notabl
rate
higher
rsv
uri
seven
develop
airflow
declin
lrti
six
develop
airflow
declin
steepest
declin
fev
occur
within
day
infect
howev
patient
continu
progress
obstruct
day
among
lung
transplant
recipi
typic
symptom
piv
includ
cough
short
breath
sob
fever
infiltr
respiratori
failur
furthermor
piv
progress
uri
lrti
occur
ltr
piv
secondari
bacteri
infect
pseudomona
staphylococcu
occur
case
importantli
piv
like
abl
activ
mediat
allograft
reject
allograft
injuri
support
studi
suggest
piv
associ
acut
chronic
reject
instanc
overal
advers
outcom
declin
fev
acut
reject
occur
patient
piv
median
time
interv
allograft
injuri
month
although
clinic
data
suggest
possibl
role
piv
develop
allograft
dysfunct
bronchiol
obliteran
syndrom
bo
studi
requir
notabl
also
report
allograft
reject
injuri
associ
piv
infect
renal
liver
transplant
patient
diagnosi
nasopharyng
aspir
bal
sampl
sent
viral
cultur
dfa
test
nat
detect
respiratori
virus
increasingli
use
detect
piv
offer
increas
sensit
detect
posit
pcr
demonstr
dfaneg
subject
effect
infect
control
procedur
includ
isol
atrisk
patient
outand
inpati
clinic
set
enforc
studi
identifi
closecontact
transmiss
surfac
contamin
least
import
droplet
spread
direct
hand
contact
piv
transmiss
infecti
viru
demonstr
hour
skin
cloth
present
drug
licens
us
food
drug
administr
treatment
piv
infect
children
adult
absenc
robust
clinic
efficaci
data
larg
random
control
studi
licens
treatment
avail
institut
offer
ribavirin
basi
evid
vitro
vivo
activ
parainfluenza
virus
case
report
small
seri
sialic
acid
analogu
zanamivir
design
interfer
bind
viral
hemagglutinin
ha
neuraminidas
na
host
sialic
acid
residu
origin
design
inhibit
influenza
infect
partial
activ
inhibit
vitro
yet
evid
vivo
activ
similar
drugscompound
block
hemagglutinin
neuraminidas
ha
na
piv
bcx
bcx
show
promis
although
human
clinic
trial
need
influenza
common
caus
respiratori
infect
immunocompet
immunocompromis
host
includ
sot
recipi
although
major
influenza
infect
mild
worldwid
influenza
remain
lead
caus
death
infect
due
season
epidem
sporad
pandem
emerg
spread
zoonot
influenza
strain
includ
avian
novel
swine
virus
global
economi
place
world
human
popul
constant
risk
influenza
pandem
season
influenza
infect
occur
winter
month
although
case
pandem
occur
yearround
estim
gener
popul
infect
annual
although
actual
incid
difficult
determin
mani
mild
case
go
undetect
similar
incid
influenza
infect
report
among
transplant
recipi
despit
immunocompromis
state
report
literatur
retrospect
case
seri
therefor
frequenc
influenza
infect
among
transplant
recipi
like
underestim
wherea
sever
infect
may
overrepres
due
mani
milder
case
go
unreport
occur
time
posttransplant
incid
highest
recipi
hsct
ltr
among
hsct
recipi
report
unit
state
europ
gener
describ
low
rate
influenza
infect
allogen
sct
recipi
higher
risk
contract
influenza
rvi
larg
analysi
hsct
recipi
document
incid
first
day
alon
transplant
surprisingli
studi
transplant
influenza
season
signific
risk
factor
develop
influenza
infect
patient
higher
dose
corticosteroid
ie
mgkg
allogen
transplant
recipi
longer
durat
viral
shed
rais
risk
transmiss
among
sot
recipi
incid
influenza
infect
highest
lung
transplant
recipi
studi
analyz
case
influenza
infect
adult
sot
recipi
univers
pittsburgh
reveal
case
period
case
occur
among
ltr
result
incid
person
year
studi
five
case
report
among
liver
transplant
recipi
six
among
renal
transplant
recipi
underscor
rel
low
incid
influenza
infect
report
frequenc
influenza
infect
among
sot
recipi
center
rang
report
describ
incid
limit
studi
pandem
influenza
report
incid
rate
among
ltr
howev
although
overal
incid
influenza
infect
low
influenza
virus
still
remain
common
caus
rvi
among
transplant
recipi
furthermor
rate
complic
higher
among
transplant
recipi
gener
popul
see
later
discuss
transmiss
influenza
occur
infecti
droplet
spread
directli
sneez
cough
indirectli
via
fomit
nosocomi
transmiss
frequent
report
particularli
transplant
unit
highlight
import
infect
control
practic
care
immunocompromis
patient
isol
precaut
droplet
observ
airborn
precaut
case
suspect
pandem
strain
transmiss
influenza
transplant
infect
allograft
report
case
appear
rare
mainli
occur
lung
transplant
guidelin
transplant
societi
issu
pandem
recommend
lung
recov
transplant
donor
influenza
infect
small
intestin
addit
recov
donor
pandem
influenza
organ
consid
transplant
treatment
appropri
antivir
therapi
direct
transmiss
influenza
renal
solid
organ
directli
demonstr
although
renal
allograft
acut
infect
donor
associ
delay
graft
function
addit
transmiss
influenza
occur
viru
present
stem
cell
product
report
pandem
influenza
segment
singlestrand
negativesens
rna
virus
influenza
virus
classifi
type
b
c
influenza
b
virus
major
caus
human
diseas
influenza
strain
subtyp
surfac
protein
hemagglutinin
ha
neuraminidas
na
antigen
sens
host
immun
system
also
rapidli
acquir
mutat
enabl
viru
evad
detect
prior
humor
ie
antibodymedi
immun
antigen
drift
constant
surveil
circul
influenza
strain
necessari
make
appropri
alter
vaccin
composit
annual
basi
pandem
aris
one
seven
genom
rna
segment
reassort
segment
influenza
strain
eg
swine
avian
human
result
antigen
shift
novel
swine
flu
strain
thought
arisen
reassort
event
swine
triplereassort
influenza
strain
portal
entri
nose
case
influenza
infect
limit
upper
respiratori
tract
influenza
virus
directli
infect
respiratori
epitheli
cell
caus
local
injuri
cell
death
antivir
immun
respons
result
recruit
cytotox
lymphocyt
induct
proinflammatori
cytokin
tnfa
type
interferon
occasion
particularli
immunocompromis
host
infect
spread
lower
respiratori
tract
excess
inflammatori
respons
lung
lead
lung
injuri
describ
case
season
pandem
avian
influenza
infect
paradox
aspect
antivir
immun
appear
enhanc
develop
bacteri
superinfect
result
secondari
bacteri
pneumonia
anoth
seriou
complic
influenza
viral
infect
signific
number
lower
respiratori
tract
influenza
infect
precipit
reject
transplant
allograft
includ
lung
kidney
liver
acut
reject
well
longterm
reject
ie
bo
frequent
observ
mechan
occur
entir
clear
area
intens
investig
similar
immunocompet
host
transplant
recipi
influenza
mild
selflimit
infect
upper
respiratori
tract
although
complic
common
retrospect
studi
hsct
recipi
patient
influenza
present
uri
lower
respiratori
tract
manifest
patient
present
uri
progress
pneumonia
within
day
onset
lymphopenia
significantli
associ
lrti
although
interestingli
steroid
use
appear
protect
develop
pneumonia
associ
increas
mortal
patient
invari
cough
rhinorrhea
fever
may
may
present
due
immunosuppress
state
medic
prolong
shed
viru
remain
issu
particularli
among
patient
lymphopenia
solid
organ
recipi
influenza
infect
present
frequent
respiratori
symptom
includ
rhiniti
short
breath
cough
malais
myalgia
arthralgia
also
common
complaint
unlik
pediatr
transplant
popul
virtual
patient
present
fever
adult
transplant
recipi
variabl
present
fever
howev
presenc
fever
transplant
patient
suspect
rvi
strongli
predict
influenza
infect
although
bacteri
coinfect
may
difficult
rule
pediatr
lung
hsc
transplant
recipi
particular
risk
complic
influenza
infect
pediatr
transplant
popul
seri
parainfluenza
influenza
infect
children
hospit
pittsburgh
report
three
patient
influenza
die
extens
lung
injuri
within
month
transplant
two
liver
one
heart
transplant
recipi
anoth
seri
pediatr
sot
recipi
confirm
influenza
b
infect
five
present
lrti
two
acut
respiratori
distress
syndrom
requir
mechan
ventil
five
evid
neurolog
involv
includ
one
die
cerebr
herniat
adult
retrospect
singlecent
studi
switzerland
hospit
patient
period
report
case
rvi
occur
immunocompromis
individu
largest
group
ltr
follow
bmt
recipi
thirtynin
percent
case
rvi
influenza
crude
mortal
rate
among
entir
cohort
day
fatal
case
influenza
pathogen
high
percentag
hsct
recipi
hospit
influenza
infect
develop
pneumonia
report
mortal
rate
rang
half
hsct
patient
influenzaassoci
pneumonia
evid
concomit
bacteri
fungal
infect
detail
complic
rate
hsct
recipi
follow
infect
pandem
influenza
start
emerg
report
describ
rel
similar
rate
lower
respiratori
tract
involv
season
flu
other
report
markedli
higher
mortal
rate
sever
ill
complic
influenza
infect
sot
recipi
includ
lrti
lung
injuri
acut
chronic
reject
allograft
coinfect
pathogen
among
hospit
sot
recipi
confirm
influenza
infect
develop
lrti
develop
bacteri
pneumonia
fifti
patient
underw
biopsi
transplant
organ
time
ill
demonstr
acut
allograft
reject
suggest
influenza
infect
may
precipit
acut
cellular
reject
similar
respiratori
virus
pandem
sot
patient
mainli
renal
develop
pneumonia
requir
intens
care
overal
mortal
although
transplant
patient
surviv
influenza
infect
mani
develop
longterm
complic
signific
complic
ltr
chronic
reject
bo
ltr
influenza
experi
signific
decreas
fev
persist
month
ill
lower
respiratori
tract
involv
increas
risk
bo
influenza
infect
precipit
bo
lung
transplant
recipi
previous
evid
chronic
reject
case
occur
shortli
acut
infect
persist
declin
pulmonari
function
late
acut
allograft
reject
diagnosi
multipl
microbiolog
techniqu
employ
diagnosi
influenza
virus
particularli
among
patient
complic
infect
viru
cultur
rapid
antigen
test
nat
eg
pcr
test
choic
possibl
nasopharyng
swab
wash
sent
rapid
antigen
test
yield
fastest
result
although
less
sensit
henc
neg
antigen
test
reliabl
rule
influenza
infect
viral
cultur
nat
test
high
sensit
sent
upper
respiratori
sampl
lower
respiratori
involv
bal
consid
immunocompromis
patient
pcr
nat
test
becom
test
choic
rvi
given
high
sensit
addit
nucleic
acidbas
test
determin
subtyp
influenza
epidemiolog
purpos
howev
caveat
nat
often
multipl
type
respiratori
virus
detect
may
posit
asymptomat
individu
make
difficult
determin
viru
true
pathogen
influenza
vaccin
trival
inactiv
subunit
vaccin
recommend
transplant
recipi
transplant
candid
household
contact
health
care
worker
contact
immunocompromis
patient
howev
humor
cellular
immun
respons
candid
antigen
respons
attenu
transplant
recipi
compar
normal
control
period
augment
immunosuppress
induct
agent
cytolyt
therapi
may
decreas
immunogen
vaccin
time
vaccin
adjust
accordingli
hsct
recipi
vaccin
respons
absent
month
posttranspl
recommend
wait
month
administ
vaccin
similarli
sot
recipi
vaccin
administ
time
month
posttranspl
data
support
acut
chronic
reject
consequ
vaccin
popul
live
attenu
intranas
prepar
recommend
immunocompromis
popul
avail
antivir
agent
treatment
influenza
fall
two
class
inhibitor
amantidin
rimantidin
neuraminidas
inhibitor
oseltamivir
zanamivir
emerg
resist
amantidin
rimantidin
recommend
treatment
influenza
viral
infect
henc
oral
oseltamivir
inhal
zanamivir
treatment
choic
influenza
infect
agent
shown
uncontrol
studi
well
toler
may
prevent
progress
diseas
immunocompromis
host
control
studi
transplant
patient
lack
optim
durat
known
present
howev
sinc
transplant
recipi
often
prolong
durat
viral
shed
consider
given
extend
durat
treatment
day
evid
viral
shed
ceas
base
upon
weekli
pcr
test
normal
host
adv
infect
frequent
associ
selflimit
uri
pharyng
coryza
etc
gastrointestin
ill
conjunctiv
diseas
adenovirus
worldwid
distribut
signific
season
variat
sever
dissemin
adv
infect
although
rare
immunocompet
host
occur
immunocompromis
patient
augment
immunosuppress
includ
exposur
cytolyt
therapi
consid
risk
factor
sever
diseas
patient
experi
adv
infect
adv
infect
typic
caus
exposur
infect
respiratori
secret
persontoperson
contact
transmiss
occur
via
inhal
aerosol
droplet
direct
conjunctiv
inocul
fecalor
spread
exposur
infect
tissu
blood
incub
period
rang
day
donor
organassoci
transmiss
adv
describ
adv
may
also
establish
latenc
lymphoid
tissu
reactiv
occur
initi
immun
suppress
adv
increasingli
recogn
pathogen
patient
follow
hsct
highest
risk
period
adv
infect
within
first
day
transplant
among
hsct
recipi
children
higher
incid
adv
infect
adult
addit
risk
factor
among
hsct
recipi
includ
allogen
hsct
hla
human
leukocyt
antigen
mismatch
sever
cell
deplet
gvhd
among
sot
recipi
risk
factor
adv
infect
includ
pediatr
recipi
receipt
antilymphocyt
antibodi
adv
serolog
mismatch
donorposit
recipientneg
prospect
surveil
studi
sot
recipi
adv
viremia
detect
patient
first
posttranspl
year
includ
liver
recipi
kidney
recipi
heart
recipi
major
patient
symptom
patient
recov
spontan
contrast
retrospect
studi
report
seriou
infect
poor
outcom
sot
recipi
review
pediatr
liver
transplant
recipi
develop
adv
infect
nine
death
attribut
adv
diseas
anoth
review
adult
liver
transplant
recipi
diagnos
adv
infect
two
advrel
death
pediatr
heart
transplant
recipi
presenc
adv
dna
cardiac
biopsi
associ
poor
graft
surviv
adv
also
associ
hemorrhag
cystiti
graft
dysfunct
adult
renal
transplant
recipi
molecular
surveil
studi
ltr
use
pcr
patient
develop
adv
viremia
first
year
posttranspl
asymptomat
recov
spontan
associ
subsequ
allograft
reject
dysfunct
note
sever
adenovir
infect
lung
transplant
less
common
associ
graft
dysfunct
fatal
diseas
review
ltr
four
diagnos
adv
infect
includ
pediatr
recipi
adult
recipi
four
develop
sever
necrot
pneumonia
die
within
day
transplant
anoth
studi
pediatr
ltr
adv
infect
diagnos
eight
result
two
earli
death
well
late
graft
loss
oblit
bronchiol
ob
case
fatal
adv
pneumonia
adult
ltr
year
transplant
describ
fiftythre
serotyp
seven
speci
g
adv
recogn
howev
one
third
serotyp
associ
human
diseas
global
serotyp
commonli
associ
human
diseas
differ
serotyp
display
differ
tissu
trophism
correl
clinic
manifest
infect
discuss
adenoviru
articl
issu
ineffect
cellular
immun
risk
factor
adv
infect
cellmedi
immun
import
recoveri
increas
lymphocyt
count
count
associ
clearanc
adv
infect
improv
surviv
humor
respons
also
play
import
role
control
adv
infect
serotypespecif
neutral
antibodi
correl
clearanc
adv
patient
whose
viremia
clear
exhibit
increas
humor
respons
eightto
increas
serotypespecif
antibodi
clinic
manifest
immunocompromis
patient
includ
pneumonia
hepat
hemorrhag
cystiti
coliti
pancreat
meningoenceph
dissemin
diseas
depend
underli
diseas
affect
organ
system
patient
age
viru
serotyp
among
sot
recipi
transplant
organ
common
site
diseas
spectrum
advassoci
syndrom
broad
part
due
variou
serotyp
discuss
elsewher
issu
immunocompromis
patient
adv
infect
tend
prolong
sever
sometim
fatal
multipl
approach
avail
diagnos
adv
infect
convent
viral
cultur
sensit
specif
method
usual
yield
characterist
cytopath
effect
day
occasion
may
take
day
serotyp
shell
vial
cultur
techniqu
improv
speed
diagnosi
compar
convent
cultur
viral
antigen
assay
provid
rapid
diagnosi
sensit
test
limit
pcr
techniqu
adv
plasma
urin
infect
fluid
tissu
highli
sensit
among
transplant
recipi
pcr
assay
blood
stool
sampl
may
effect
way
screen
asymptomat
patient
facilit
earli
preemptiv
therapi
howev
role
routin
surveil
controversi
pcr
quantif
viral
load
use
monitor
respons
therapi
adv
also
caus
characterist
intranuclear
inclus
seen
biopsi
occasion
adv
inclus
may
confus
cmv
inclus
advspecif
immunohistochem
stain
avail
current
clinic
avail
adv
vaccin
given
potenti
nosocomi
spread
infect
control
measur
critic
transplant
clinic
inpati
unit
notabl
hand
wash
may
reliabl
remov
adv
contamin
finger
outbreak
control
cohort
patient
use
glove
gown
goggl
exclud
symptomat
staff
unit
regard
treatment
establish
adv
infect
prospect
trial
lack
antivir
drug
approv
treat
adv
ganciclovir
ribavirin
vidarabin
limit
vitro
activ
adv
case
report
small
seri
report
success
outcom
treatment
imposs
determin
whether
patient
would
recov
without
therapi
cidofovir
cdv
cytosin
nucleotid
analogu
inhibit
dna
polymeras
greatest
vitro
activ
adv
prefer
therapeut
agent
cdv
avail
intraven
base
upon
pharmacokinet
properti
dose
weekli
common
dose
regimen
mgkg
weekli
dose
regimen
report
includ
mgkg
thrice
weekli
children
durat
therapi
depend
upon
clinic
respons
largest
publish
seri
hsct
patient
treat
cdv
clear
adv
infect
multipl
smaller
seri
adv
infect
hsct
recipi
variabl
present
improv
cdv
treatment
although
cdv
gener
well
toler
potenti
nephrotox
especi
use
combin
nephrotox
drug
problemat
hydrat
probenacid
may
minim
nephrotox
care
monitor
renal
function
critic
cell
immun
play
critic
role
control
adv
infect
level
immunosuppress
reduc
feasibl
howev
also
evid
use
immunotherapi
immunosuppress
patient
primarili
hsct
recipi
small
seri
adopt
transfer
virusspecif
lymphocyt
pediatr
hsct
recipi
report
posit
outcom
pool
ivig
commonli
use
adjunct
therapi
cdv
antivir
medic
data
insuffici
assess
efficaci
importantli
patient
adv
infect
viremia
requir
treatment
patient
asymptomat
time
viremia
spontan
resolut
common
reserv
treatment
symptomat
patient
dissemin
preemptiv
therapi
may
role
virem
asymptomat
organ
transplant
recipi
high
risk
dissemin
prospect
random
trial
need
elucid
indic
therapi
symptomat
asymptomat
patient
adv
infect
human
metapneumoviru
hmpv
paramyxoviru
close
relat
rsv
nearli
univers
encount
year
age
second
rsv
caus
bronchiol
children
etiolog
lrti
hospit
children
hmpv
circul
yearround
temper
climat
found
often
late
winter
spring
viru
first
describ
van
den
hoogen
et
al
respiratori
sampl
children
present
clinic
syndrom
compat
rsv
hmpv
caus
sever
diseas
normal
immunocompromis
popul
survey
infant
intub
rsv
bronchiol
underw
bal
coinfect
hmpv
detect
pcr
importantli
infant
underli
risk
factor
sever
rsv
diseas
coinfect
hmpv
suggest
hmpv
caus
coprecipit
sever
diseas
nonimmunocompromis
popul
patient
hospit
hsct
hematolog
cancer
patient
posit
hmpv
children
patient
evid
infiltr
chest
radiograph
retrospect
studi
sampl
patient
hsct
hmpv
pcr
three
radiograph
evid
pneumonia
hmpv
bal
one
patient
die
sepsi
coinfect
influenza
b
ltr
uri
lrti
symptom
viru
detect
pcr
hmpv
much
higher
percentag
hmpv
studi
patient
requir
intub
patient
hmpv
requir
hospit
acut
allograft
dysfunct
survey
outpati
ltr
found
patient
symptom
either
uri
lrti
bal
nasopharyng
swab
posit
respiratori
viru
pcr
hmpv
repres
posit
sampl
garbino
et
al
note
lung
transplant
bal
sampl
posit
respiratori
viru
hmpv
survey
ltr
weinberg
found
episod
respiratori
infect
episod
least
one
respiratori
viru
detect
pcr
seven
hmpv
four
sole
pathogen
hmpv
infect
requir
hospit
occur
rate
similar
piv
rsv
clinic
diagnos
acut
reject
ie
biopsi
often
seen
rsv
hmpv
studi
found
hmpv
caus
sever
diseas
moreov
detect
viral
nucleic
acid
alon
signifi
diseas
situat
like
case
surveil
bronchoscopi
lung
transplant
exampl
ltr
undergo
bal
surveil
bal
posit
respiratori
viru
three
time
like
come
asymptomat
versu
symptomat
patient
four
hmpv
case
asymptomat
host
present
hmpv
gener
uri
yet
fever
cough
dyspnea
pneumonia
wheez
report
frequent
common
immunocompromis
individu
wheez
may
less
frequent
patient
hmpv
compar
patient
rsv
studi
identifi
hmpv
symptom
adult
hsct
patient
respiratori
sampl
examin
hmpv
infect
pcr
posit
three
coinfect
anoth
viru
seventytwo
percent
patient
uri
wherea
remaind
evid
pneumonia
none
die
least
one
instanc
hmpv
detect
lung
tissu
situ
hybrid
open
lung
biopsi
unusu
present
uri
meningoenceph
similar
nipah
viru
anoth
paramyxoviru
boy
associ
hmpv
lung
brain
tissu
pcr
histopatholog
given
hmpv
sever
ill
particularli
immunocompromis
possibl
predict
develop
sever
diseas
use
sampl
hsct
popul
campbel
found
seven
patient
hmpv
pcr
although
quantit
viral
load
associ
need
mechan
ventil
death
detect
viral
nucleic
acid
specif
hmpv
serum
significantli
associ
death
virus
comparison
diagnost
sensit
cultur
immunofluoresc
pcr
demonstr
pcr
sensit
studi
hsct
patient
includ
hmpv
comparison
unexpectedli
found
pcr
twice
sensit
cultur
four
time
sensit
immunofluoresc
howev
detect
pcr
alon
associ
lower
viral
load
fewer
respiratori
symptom
serolog
determin
exposur
also
possibl
ribavirin
use
treatment
least
one
publish
studi
ribavirin
ivig
appear
near
equal
efficaci
hmpv
vitro
reduct
steroid
dose
may
also
gener
benefit
least
reduc
chanc
infect
respiratori
virus
human
coronaviru
hcov
associ
uri
one
common
cold
virus
may
also
caus
bronchiol
croup
children
rna
viru
coronavirida
famili
present
four
genotyp
nonsar
hcov
identifi
four
genotyp
found
upper
lower
respiratori
tract
immunocompromis
patient
temper
zone
viru
may
predilect
winter
transmiss
littl
evid
season
transmiss
hcov
prospect
evalu
adult
hospit
acut
respiratori
ill
bal
patient
assess
hcov
found
bal
hcov
sot
recipi
patient
hematolog
cancer
preval
final
bal
patient
respiratori
viru
nucleic
acid
found
hcov
survey
respiratori
viru
infect
adult
ltr
found
hcov
account
virus
detect
either
bal
nasopharyng
swab
wherea
hsct
patient
four
bal
sampl
found
hcov
limit
data
regard
clinic
present
viru
immunocompromis
host
outsid
uri
one
studi
ltr
hcov
bal
asymptomat
patient
bronchoscopi
surveil
milano
perform
yearlong
survey
weekli
respiratori
symptom
viral
detect
pcr
respiratori
sampl
first
day
hsct
day
cumul
incid
hcov
patient
asymptomat
time
viru
identifi
none
patient
hcov
uri
symptom
develop
lrti
first
day
three
person
hcov
shed
viral
nucleic
acid
least
month
isol
hcov
statist
associ
symptom
regress
analysi
two
case
report
sever
diseas
first
hcov
lrti
shortli
treatment
solid
tumor
second
immunocompromis
adult
hsct
develop
uri
hcov
ultim
die
progress
respiratori
failur
without
identif
pathogen
diagnosi
hcov
made
pcr
hcov
includ
multiplex
pcr
assay
multitud
respiratori
virus
specif
treatment
human
rhinoviru
hrv
picornaviru
preval
common
cold
viru
peak
incid
earli
fall
three
recogn
genotyp
b
c
circul
year
round
viru
ubiquit
estim
year
everi
adult
one
hrv
infect
one
studi
found
adult
cold
symptom
picornaviru
infect
hrv
gener
commonli
isol
respiratori
viru
hsct
ltr
exampl
patient
underw
combin
bal
respiratori
viral
nucleic
acid
detect
pcr
hrv
preval
virus
test
furthermor
multicent
studi
respiratori
virus
pediatr
ltr
found
infect
due
hrv
clinic
present
hrv
gener
uri
coryza
cough
studi
hrv
associ
sever
diseas
though
report
sever
even
fatal
diseas
possibl
attribut
hrv
exist
inde
adult
ltr
hrv
detect
bal
like
asymptomat
symptomat
vs
liu
found
respiratori
virus
pediatr
ltr
hrv
associ
death
subsequ
bo
occurr
pediatr
bone
marrow
unit
patient
hrv
detect
nasopharyng
aspir
either
asymptomat
coryza
without
lrti
surviv
associ
hrv
lrti
found
studi
bal
immunocompromis
patient
includ
ltr
howev
degre
immunosuppress
influenc
likelihood
develop
lrti
retrospect
cohort
studi
evalu
effect
rvi
includ
hrv
patient
undergo
nonmyeloabl
versu
myeloabl
chemotherapi
versu
autohsct
patient
incid
rvi
statist
less
autohsct
lrti
less
common
nonmyeloabl
versu
two
immunocompromis
group
look
enteroviru
hrv
patient
hematolog
malign
hrv
found
pcr
four
sign
lrti
two
patient
develop
lrti
subsequ
uri
howev
onehalf
hrv
lrti
case
associ
coinfect
organ
known
caus
lrti
death
associ
hrv
anoth
studi
hsct
patient
first
day
posthsct
found
hrv
patient
hrvposit
patient
coryza
cough
present
three
patient
progress
lrti
prolong
shed
hrv
immunocompromis
patient
occur
aforement
studi
hsct
patient
median
shed
time
hrv
week
wherea
shed
month
small
studi
adult
ltr
three
case
prolong
shed
hrv
one
month
given
common
respiratori
virus
progress
lrti
vulner
patient
sever
diseas
predict
viral
load
hrv
gerna
et
al
look
immunocompromis
children
hsct
recipi
adult
ltr
normal
children
adult
found
immunocompromis
adult
tend
lower
pcr
count
asymptomat
wherea
immunolog
normal
children
higher
viral
load
associ
sever
diseas
overal
viral
load
associ
lrti
indirect
effect
common
respiratori
pathogen
acut
chronic
reject
assess
costa
et
al
found
effect
ltr
although
specif
hrv
least
one
report
suggest
associ
rvi
subsequ
acut
chronic
reject
detect
viral
nucleic
acid
pcr
sensit
method
cultur
dfa
also
possibl
albeit
lower
sensit
present
licens
specif
treatment
ivig
use
sever
case
along
reduct
steroid
immunosuppress
pleconaril
efficaci
treatment
hrv
submit
fda
consider
reject
secondari
safeti
concern
present
licens
unit
state
prelicens
trial
pleconaril
reduc
durat
symptom
averag
day
coryza
significantli
improv
compar
placebo
second
day
newli
describ
parvoviru
human
bocaviru
hbov
discov
alland
et
al
use
univers
viral
pcr
primer
respiratori
sampl
pathogen
identifi
time
discoveri
author
perform
small
epidemiolog
studi
found
children
admit
hospit
uri
wheez
hbov
detect
pcr
upper
respiratori
sampl
children
viral
pathogen
identifi
respiratori
sampl
broad
pcr
base
approach
identifi
coinfect
undertaken
incid
hbov
vari
children
uri
like
parvovirus
human
anim
viru
found
respiratori
secret
like
transmit
via
respiratori
droplet
howev
dissemin
hbov
describ
plasma
stool
thu
passag
via
bodili
fluid
yet
exclud
appear
strong
season
hbov
found
year
around
major
studi
use
detect
hbov
pcr
nasopharynx
children
sampl
lower
respiratori
tract
bal
even
fewer
assess
carriag
transplant
patient
garbino
et
al
assess
bal
sampl
patient
respiratori
virus
pcr
hbov
least
frequent
detect
viru
frequenc
anoth
studi
bal
sampl
year
half
found
neglig
differ
hbov
detect
rate
sot
hsct
nontranspl
patient
sampl
hbov
clinic
symptom
lrti
yet
one
hbov
sampl
anoth
signific
respiratori
pathogen
time
clinic
present
australian
studi
bal
sampl
patient
includ
ltr
hbov
dna
detect
patient
clinic
present
hbov
present
well
defin
may
includ
fever
uri
wheez
lrti
diarrhea
earli
report
schenk
et
al
note
dissemin
hbov
infect
child
allogen
hsct
transplant
develop
nonspecif
febril
episod
patient
hbov
dna
detect
nasopharynx
blood
stool
multipl
occas
preand
postengraft
report
mere
highlight
fact
viru
may
dissemin
immunocompromis
individu
without
clear
syndrom
inde
dissemin
hbov
may
rule
except
prospect
collect
nasopharyng
fecal
sampl
children
young
adult
acut
gastroenter
neg
screen
common
respiratori
virus
detect
hbov
nasopharyng
fecal
sampl
wateri
diarrhea
fever
common
symptom
hbov
stool
howev
nasopharyng
fecal
sampl
coinfect
anoth
potenti
pathogen
make
difficult
ascrib
clinic
find
hbov
alon
similarli
vicent
et
al
found
hbov
fecal
sampl
children
acut
gastroenter
respiratori
sampl
children
symptom
uri
studi
respiratori
sampl
coinfect
anoth
respiratori
viru
wherea
fecal
sampl
addit
pathogen
identifi
least
one
studi
suggest
seriou
clinic
present
possibl
children
year
age
children
hbov
present
bronchiol
bronchopneumonia
half
case
coinfect
anoth
respiratori
viru
similar
rate
hbov
dna
isol
case
control
commonli
found
surveil
studi
hbov
dna
nasopharynx
alon
like
suffici
diagnosi
hbov
diseas
relat
parvoviru
may
take
time
figur
exactli
role
hbov
differ
clinic
syndrom
also
often
found
respiratori
secret
caus
respiratori
diseas
furthermor
close
relat
parvovirus
anim
tend
caus
nonrespiratori
diseas
thu
time
difficult
speak
certainti
regard
clinic
syndrom
attribut
newli
describ
human
parvoviru
diagnosi
base
upon
presenc
hbov
dna
pcr
rise
igm
igg
antibodi
titer
specif
treatment
respiratori
virus
increasingli
recogn
signific
risk
factor
develop
bo
ob
histopatholog
hallmark
chronic
lung
allograft
reject
fibroprolif
small
airway
diseas
thought
preced
inflamm
epitheli
injuri
mucos
ulcer
clinic
ob
manifest
progress
airflow
limit
dysfunct
lung
allograft
bo
lead
respiratori
disabl
ultim
death
develop
bo
import
factor
limit
longterm
surviv
lung
transplant
patient
affect
within
year
transplant
notabl
chronic
pulmonari
gvhd
hsct
may
also
produc
progress
airflow
declin
risk
syndrom
also
increas
follow
rvi
addit
epidemiolog
studi
preclin
model
also
suggest
rvi
may
potenti
reject
viral
infect
caus
reject
skin
allograft
otherwis
toler
host
winter
et
al
demonstr
murin
sendai
viru
close
relat
human
augment
airway
damag
allogen
syngen
nontranspl
rat
lung
allograft
subsequ
studi
murin
orthotop
tracheal
transplant
model
oblit
airway
diseas
demonstr
increas
airway
fibrosi
allograft
infect
sendai
viru
research
need
delin
immun
mechan
contribut
postvir
chronic
allograft
dysfunct
lung
transplant
recipi
import
rvi
continu
gain
recognit
hsct
sot
recipi
understand
continu
evolv
due
chronic
immun
suppress
patient
particularli
suscept
sever
diseas
uncommon
gener
popul
also
recogn
rvi
may
import
indirect
consequ
includ
coinfect
potenti
lung
allograft
reject
newer
molecular
techniqu
allow
rapid
identif
identif
greater
number
virus
howev
signific
abil
detect
rvi
transplant
recipi
mani
minim
symptom
remain
determin
importantli
treatment
option
rvi
limit
prevent
infect
infect
control
measur
immun
pathogen
vaccin
avail
import
